Association of RAD51 with Homologous Recombination Deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial

Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer

(2020) Neha Chopra et al.   Nature Communications

Olaparib monotherapy as primary treatment in unselected triple negative breast cancer

(2020) H.P. Eikesdal et al.   ANNALS OF ONCOLOGY

Genomic characterization of metastatic breast cancers

(2019) François Bertucci et al.   NATURE

Tumour lineage shapes BRCA-mediated phenotypes

(2019) Philip Jonsson et al.   NATURE

RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer

(2018) C Cruz et al.   ANNALS OF ONCOLOGY

Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial

(2018) Sibylle Loibl et al.   LANCET ONCOLOGY

Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial

(2018) Andrew Tutt et al.   NATURE MEDICINE

Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto

(2018) S Loibl et al.   ANNALS OF ONCOLOGY

A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation

(2018) Marta Castroviejo‐Bermejo et al.   EMBO Molecular Medicine

HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures

(2017) Helen Davies et al.   NATURE MEDICINE

Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer

(2017) Eric Hahnen et al.   JAMA Oncology

Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer

(2016) M. L. Telli et al.   CLINICAL CANCER RESEARCH

Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)

(2015) William M. Sikov et al.   JOURNAL OF CLINICAL ONCOLOGY

TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer

(2015) Steven J. Isakoff et al.   JOURNAL OF CLINICAL ONCOLOGY

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial

(2014) Gunter von Minckwitz et al.   LANCET ONCOLOGY

Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer

(2012) V Abkevich et al.   BRITISH JOURNAL OF CANCER

A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer

(2010) M. Graeser et al.   CLINICAL CANCER RESEARCH